The latest news from academia, regulators
research labs and other things of interest
Posted: Nov 25, 2013
Handbook of personalized medicine: Advances in nanotechnology, drug delivery and therapy
(Nanowerk News) This book compiles multidisciplinary efforts of recent advancements in pharmacology, nanotechnology, genomics, informatics and therapeutics aiming to conceptualize the environment in research and clinical setting that creates the fertile ground for the practical utility of personalized medicine decisions and also enables clinical pharmacogenomics for establishing pharmacotyping in drug prescription, i.e. the individualized drug and dosage scheme selection based on clinical and genetic data. Within this context, its chapter organization is unique, including innovative drug formulations and nanotheranostics, molecular imaging and signatures, translational nanomedicine and informatics, stem cell therapy approaches, modeling and predictability of drug response, pharmacogenetics-guided drug prescription, pharmacovigilance and regulatory aspects, ethical and cost-effectiveness issues, pharmacogenomics knowledge bases, personal genome sequencing, molecular diagnostics, education and training, as well as last, but not least, information-based medicine to support unified workflow infrastructure in everyday clinical practice worldwide.
This book is unique in its concept by featuring crucial multidisciplinary cutting-edge advancements that possess the potential to enable practical and broad utility of personalized medicine decisions in prognosis, diagnosis and drug delivery
The central idea to present interdisciplinary thematic issues contributing to wide, feasible and cost-affordable implementation of personalized medicine and pharmacogenomics into routine healthcare is innovative, comprehensive and informative
The topics compiled and discussed within the various chapters are presented by leading scientists actively engaged in research within their area of expertise
“The integration of several concepts and technologies to make personalized medicine an efficient daily practice has been quite difficult but a critical issue of vast importance. Handbook of Personalized Medicine represents a genuine effort to achieve such a long-term goal. A major source of information written in a well-organized fashion in more than 1500 pages, this handbook is the result of long-term hard work of both the editor and the contributors and covers almost everything directly or indirectly related to personalized medicine, including nanotechnologies, materials needed for specific drug delivery systems, medical imaging technologies, pharmacogenomics, drug response variability, drug metabolism and toxicity, pharmacotyping, bioequivalence and pharmakokinetics, as well as bioinformatics and model construction to facilitate improvement of drug delivery and therapy. Each chapter has been contributed by active investigators who are well-known experts and come from different countries and various sectors: academia, pharmaceutical industry, computer companies, pharmacy, and clinical medicine. The book can be of added value to every scientist, investigator or regulator, pharmacist or clinical pharmacologist, developer in pharmaceutical industry, and to teachers in academia as well as students. It fills a gap in the provocative field of personalized medicine.”
Prof. Asterios S. Tsiftsoglou - Aristotle University of Thessaloniki, Greece
About the Editor
Ioannis S. Vizirianakis currently serves as an Associate Professor in Molecular Pharmacology and Pharmacogenomics at Aristotle University of Thessaloniki (A.U.Th.), School of Pharmacy. After receiving his degree in Pharmacy (1981) in A.U.Th., he joined the Department as research assistant (1985-1990), obtained a Ph.D. (1991) in Biochemical Pharmacology and finally was assigned as Lecturer (1993) and then Assistant Professor (2003) in Pharmacology. He received a research grant award (1998) from Cancer Coordinating Committee upon his sabbatical at the Tumor Biology Laboratory, UCSF. He has co-authored more than 50 papers and book chapters in peer-reviewed journals and published books, whereas he has also served as reviewer to more than 18 international journals. He is member of the editorial board in the journals “Frontiers in Pharmacogenetics and Pharmacogenomics” and “World Journal of Pharmacology”, whereas he recently acted as theme editor for the journal “Advanced Drug Delivery Reviews” in the issue of “Personalized Nanomedicine” (October 2012). His long-term research interests focus on: a) the so-called “differentiation therapy of cancer” and include the development of innovative drug molecules through understanding crucial molecular mechanisms that govern leukemia cell initiation, unrestricted growth as well as blockade of differentiation and apoptosis; b) the development of innovative therapeutics for haematopoiesis disorders, e.g. ribosomopathies, through uncovering specific molecular pathophysiological mechanisms as potential pharmacological targets and their clinical validation; c) the integration of pharmacogenomics, personalized medicine and nanomedicine concepts in new drug development, drug delivery and clinical practice; and d) the application of predictive population-based physiologically-based PD/PK models for the individualization of drug dosage regimens in routine healthcare.
Source: Pan Stanford Publishing
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!